Hi burner_7, In retrospect, 'lifespan' was a poor word choice,...

Hi burner_7,

In retrospect, 'lifespan' was a poor word choice, for what I should have referred to as 'period of meaningful revenue generating capacity'.

This is based on the double whammy of each additional generic added to the market decreasing both the market share and the drug price.

The generic drug price relative to the price of the branded drug goes from an average of:

94% during the 180 day exclusivity period
52% with one other generic on the market
32% with five generic drugs on the market

Multiply that by the decreasing market share and given an expectation for generics to continue entering the market until it's no longer economically feasible to do so....that's where I get my poorly termed "short lifespan".

Hence the need for a deep and regularly replenished pipeline. From the limited data I've gathered thus far, other like companies are assigning approximately 25% of revenues to R&D. It will be interesting to see Acrux's commitment to R&D once/if revenues climb toward those previously achieved by Axiron, as anticipated in 3-4 years.